Sen-Jam Pharma launches Phase II trial of hangover prevention treatment - MSN

Sen-Jam Pharmaceutical's SJP-002C demonstrated a strong safety profile in a Phase 2 clinical trial, with no adverse events reported during the study.

Sen-Jam Pharmaceutical's SJP-001, an over-the-counter therapeutic, has received ethics approval for a clinical trial in Australia.

ShiraTronics has initiated its RELIEV-CM2 study, implanting its neuromodulation device in chronic migraine patients across the US and Australia to assess therapeutic effects.

Sen-Jam Pharmaceutical has initiated a Phase 2 clinical trial in Australia for SJP-001, a novel therapy aimed at preventing hangovers by targeting inflammation.

Sen-Jam Pharmaceutical has launched a Phase II trial in Australia to evaluate SJP-001, a novel hangover prevention therapy combining naproxen and fexofenadine.

Sen-Jam Pharmaceutical initiates a Phase II trial in Australia to evaluate SJP-001, a novel combination of naproxen and fexofenadine, for hangover prevention.

Sen-Jam Pharmaceutical has initiated a Phase 2 clinical trial for SJP-001, a novel therapeutic targeting alcohol hangover prevention, potentially the first FDA-approved treatment in this area.

Spinogenix has initiated a Phase 2 clinical trial to evaluate SPG302, a novel synaptic regenerative therapy, for the treatment of schizophrenia.

Servier and Clariness are collaborating on a Phase II trial to develop a novel biological therapy for primary Sjögren's syndrome, an autoimmune disease affecting salivary and lacrimal glands.

Sen-Jam Pharmaceutical has successfully completed participant enrollment for the Phase 2 clinical trial of its therapeutic, SJP-002C, aimed at treating Upper Respiratory Infections (URIs) and COVID. The trial, conducted in partnership with Duke University, achieved full enrollment of 150 participants, with no serious side effects reported. SJP-002C is a multi-targeted anti-inflammatory with antiviral capabilities, offering a potential affordable treatment option. The company plans to seek FDA approval for Phase 3 trials and is exploring partnerships for further development and commercialization.